Naslov
Effectiveness and safety of high-dose dual therapy: results of the European registry on Helicobacter pylori management (HP-EUREG)

Autori
L. Fernández-Salazar, Á. Pérez-Aísa, B. Vaira, L.V. Jonaitis, B. Tepeš, D.S. Bordin, A. Keco- Huerga, A. Lucendo Villarin, L. Vologzhanina, L. Bujanda Fernández de Piérola, N. Brglez Jurecic, A. Lanas, M. Leja, E. Mammadov, G. Babayeva, M. Caldas Álvarez, L.R. Rodrigo Sáez, F. Lerang, G. Fadieienko, R. Abdulkhakov, J.M. Huguet, O. Zaytsev, T. Ilchishina, A. Silkanovna Sarsenbaeva, I. Bakulin, A. G. Gravina, M. Perona, S. Alekseenko, J. Barrio, M. Areia, O. Núñez, P. Bogomolov, B.J. Gómez Rodríguez, M. Domínguez- Cajal, J. Gómez Camarero, S. Georgopoulos, P. Almela Notari, Ante Tonkić, R. Pellicano, H. Simsek, S. Hrubá, A. Gasbarrini, J.M. Botargues Bote, G.M. Buzas, T. Rokkas, I. Puig, O. Perez Nyssen, F. Mégraud, C. O ́Morain, J.P. Gisbert

Kolaboracija
Hp-EuReg Investigators

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
An international forum for clinical practice and research in gastroenterology: Abstract issue. United European Gastroenterology Journal 10(S8). / - , 2022, 557-557

Skup
30th United European Gastroenterology Week

Mjesto i datum
Beč, Austrija, 08.10.2022. - 11.10.2022

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Helicobacter pylori

Sažetak
Introduction: Introduction: Randomized clinical trials and meta-analyses, primarily from Asian countries, have reported good effectiveness with high-dose dual therapy (HDDT, i.e., PPIs plus high amoxicillin doses) when prescribed for H. pylorifirst-line or rescue treatment. However, combining amoxicillin with PPIs in the 1990s in several European countries yielded suboptimal results. The objective was to analyse the effectiveness, com-pliance and safety of HDDTin the European real clinical practice.Aims & Methods: Methods: International, multicenter, prospective non- interventional Registry aimed at evaluating the decisions and outcomes of H. pylori management by European gastroenterologists. All infected adult cases treated with HDDT were registered at AEG- REDCap e-CRF up to June 2021. Patients receiving HDDT (amoxicillin 1, 000 mg three times a day plus a PPI), with or without bismuth, in any treatment line and for at least 10 days, were selected for inclusion.Results: Sixty patients received HDDT (98% compliance), 19 of them as first-line and 41 as rescue treatment (2nd–6th line). Overall HDDT effec- tiveness was 52% (per-protocol) and 51% (modified intention-to- treat, mITT). First-line and rescue treatment lines were similarly effective. Cure rates were lower when patients had previously received metronidazole (mITT 32% vs. 70%, p<0.05), tetracycline (mITT 26% vs. 69%, p<0.05) or rifabutin (mITT 25% vs. 65%, p<0.005). Adding bismuth to HDDT in rescue treatment did not yield better results. Adverse event incidence was 30%, diarrhoea being the most common (20% of patients) ; no serious adverse events were reported. Conclusion: Although safe and with proven good compliance, HDDT does not represent an effective option in European first-line or rescueH. pyloritreatment, even when bismuth is added.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA